Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TROP-2

TROP-2

Brief Information

Name:Tumor-associated calcium signal transducer 2
Target Synonym:Tumor-associated calcium signal transducer 2,M1S1,TROP2,TACSTD2,Pancreatic carcinoma marker protein GA733-1,Tumor Associated Calcium Signal Transducer 2,GA733-1,Membrane Component, Chromosome 1, Surface Marker 1,Gastrointestinal Tumor-Associated Antigen GA7331,Pancreatic Carcinoma Marker Protein GA7331,Cell surface glycoprotein Trop-2,Membrane component chromosome 1 surface marker 1,40kD Glycoprotein, Identified By Monoclonal Antibody GA733,Cell Surface Glycoprotein TROP2,Epithelial Glycoprotein
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Licensing

Project item Indications Research phase Cooperation demands
BDA202204 “hard-to-treat” solid tumors (pancreatic, gastric, etc) License-out or co-development License-out or co-development

Product ListCompare or Buy

Part of Bioactivity data

MBS-K028-ELISA
 TROP-2 ELISA

Immobilized 32.6 μg TROP-2/1 mg beads can bind Anti-TROP-2 mAb with an EC50 of 0.8505 μg/mL (QC tested).

TR2-R52H9-MALS-HPLC
TROP-2 MALS images

The purity of Rabbit TROP-2, His Tag (Cat. No. TR2-R52H9) is more than 90% and the molecular weight of this protein is around 32-42 kDa verified by SEC-MALS.

Customer Reviews

Synonym Name

TACSTD2,GA733-1,M1S1,TROP2

Background

TROP-2 is a single-copy gene in human cells, and encodes a type-1 transmembrane glycoprotein which is over-expressed in various malignancies, also referred to as tumor associated calcium signal transducer 2 (TACSTD2), GA733-1 or M1S1. TROP-2 is related to epithelial cell adhesion molecule (EpCAM), also called TROP-1, gp40, and KSA. Trop-1 and Trop-2 are homologous to serum IGF-II-binding proteins and appear as signal transducers. Thus, they likely represent novel cell-surface receptors and may play a role in regulating the growth of carcinoma cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Sacituzumab govitecan IMMU-132; TROP-2-SN-38; IMMU0132; GS-0132 Approved Immunomedics Inc Trodelvy, 拓达维 Mainland China Triple Negative Breast Neoplasms Everest Medicines (Suzhou) Inc 2020-04-22 Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Brain metastases; Metastatic breast cancer; Endometrial Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Ovarian Epithelial; Pancreatic Neoplasms; Solid tumours; Carcinoma, Transitional Cell; Glioblastoma; Neoplasms; Triple Negative Breast Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Ovarian Neoplasms; Liver Failure Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PF-06664178 PF06664178; PF-06664178 Pfizer Inc Details
BL-M02D1 Phase 1 Clinical Baili-Bio (Chengdu) Pharmaceutical Co Ltd, Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Triple Negative Breast Neoplasms; Digestive System Neoplasms; Breast Neoplasms; Gastrointestinal Neoplasms Details
BIO-106 BIO-106 Phase 2 Clinical Hangzhou Baikai Biopharmaceutical Co Ltd Solid tumours; Neoplasms Details
DAC-002 JS-108; DAC-002 Phase 1 Clinical Hangzhou Dac Biotech Company Ltd Solid tumours; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Neoplasms Details
FDA018 Antibody Drug Conjugate Phase 2 Clinical Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Solid tumours; Neoplasms; Triple Negative Breast Neoplasms; Breast Neoplasms Details
KJ-103 KJ-103 Phase 1 Clinical Kisoji Biotechnology Inc Rejection of renal transplantation; Solid tumours Details
BAT-8008 BAT8008; BAT-8008 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Neoplasms Details
重组人源化抗Trop2单抗-SN38偶联物 ESG-401; STI-3258 Phase 2 Clinical Shanghai Escugen Biotechnology Co Ltd, Tot Biopharm Co Ltd Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms Details
SKB-264 SKB-264 Phase 3 Clinical Sichuan Kelun Pharmaceutical Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Breast Neoplasms; Endometrial Neoplasms; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
SHR-A1921 SHR-A1921; SHRA1921 Phase 1 Clinical Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd Solid tumours Details
Datopotamab deruxtecan Dato-DXd; DS-1062a; DS-1062 Phase 3 Clinical Daiichi Sankyo Co Ltd Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Colorectal Neoplasms; Lung Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message